A phase I trial of SAR-445399 for the treatment of inflammatory indications
Latest Information Update: 07 Nov 2023
At a glance
- Drugs SAR 445399 (Primary)
- Indications Inflammation
- Focus Adverse reactions
- 07 Nov 2023 New trial record
- 27 Oct 2023 According to Sanofi media release, first participant has been treated.